Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations

References

• Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant. 2013;13(Suppl 1):11–46.
   PubMed Web of Science ®Google Scholar
• Antignac M, Barrou B, Farinotti R, et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64(6):750–757.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141–175.
   PubMed Web of Science ®Google Scholar
• MacPhee IA. Pharmacogenetic biomarkers: cytochrome P450 3A5. Clin Chim Acta. 2012;413(17–18):1312–1317.
   PubMed Web of Science ®Google Scholar
• Elens L, Hesselink DA, van Schaik RH, et al. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. Mol Diagn Ther. 2012;16(6):331–345.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40(3):159–168.
   PubMed Web of Science ®Google Scholar
• de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92(3):366–375.
   PubMed Web of Science ®Google Scholar
• Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31(2):187–197.
   PubMed Web of Science ®Google Scholar
• Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14(3):147–154.
   PubMedGoogle Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383–391.
   PubMed Web of Science ®Google Scholar
• Santoro A, Felipe CR, Tedesco-Silva H, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011;12(9):1293–1303.
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11(9):773–779.
   PubMedGoogle Scholar
• Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53(2):123–139.
   PubMed Web of Science ®Google Scholar
• Picard N, Bergan S, Marquet P, et al. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs. Ther Drug Monit. 2016;38(Suppl 1):S57–S69.
   PubMed Web of Science ®Google Scholar
• Ruiz J, Herrero MJ, Boso V, et al. Impact of Single Nucleotide Polymorphisms (SNPs) on immunosuppressive therapy in lung transplantation. Int J Mol Sci. 2015;16(9):20168–20182.
   PubMed Web of Science ®Google Scholar
• Yang TH, Chen YK, Xue F, et al. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract Suppl. 2015;183:53–62.
   PubMedGoogle Scholar
• MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4(6):914–919.
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics. 2008;18(4):339–348.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant. 2005;19(5):638–643.
   PubMed Web of Science ®Google Scholar
• Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;16(9):659–665.
   PubMed Web of Science ®Google Scholar
• Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007;81(2):228–234.
   PubMed Web of Science ®Google Scholar
• Rong G, Jing L, Deng-Qing L, et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc. 2010;42(9):3455–3458.
   PubMed Web of Science ®Google Scholar
• Glowacki F, Lionet A, Buob D, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 2011;26(9):3046–3050.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Garcia M, Macias RM, et al. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int. 2012;25(4):471–480.
   PubMed Web of Science ®Google Scholar
• Ferraresso M, Tirelli A, Ghio L, et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant. 2007;11(3):296–300.
   PubMed Web of Science ®Google Scholar
• Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609–618.
   PubMed Web of Science ®Google Scholar
• Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721–726.
   PubMed Web of Science ®Google Scholar
• Pallet N, Etienne I, Buchler M, et al. Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype. Am J Transplant. 2016. DOI:10.1111/ajt.13788.
   PubMed Web of Science ®Google Scholar
• Shuker N, Bouamar R, van Schaik RH, et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2015. DOI:10.1111/ajt.13691.
   PubMed Web of Science ®Google Scholar
• Brunet M, Shipkova M, van Gelder T, et al. Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation. Ther Drug Monit. 2016;38(Suppl 1):S1–S20.
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245–254.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007;82(6):711–725.
   PubMed Web of Science ®Google Scholar
• Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation. 2008;86(9):1206–1213.
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Grady B, Choi L, et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics. 2012;22(1):32–42.
   PubMed Web of Science ®Google Scholar
• Wang D, Sadee W. CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet Genomics. 2016;26(1):40–43.
   PubMed Web of Science ®Google Scholar
• Elens L, Van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12(10):1383–1396.
   PubMed Web of Science ®Google Scholar
• Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57(11):1574–1583.
   PubMed Web of Science ®Google Scholar
• Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608–616.
   PubMed Web of Science ®Google Scholar
• Gijsen VM, van Schaik RH, Elens L, et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics. 2013;14(9):1027–1036.
   PubMed Web of Science ®Google Scholar
• Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96(3):340–348.
   PubMed Web of Science ®Google Scholar
• Werk AN, Lefeldt S, Bruckmueller H, et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther. 2014;95(4):416–422.
   PubMed Web of Science ®Google Scholar
• Hart SN, Zhong XB. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2008;4(4):439–452.
   PubMed Web of Science ®Google Scholar
• Huang N, Agrawal V, Giacomini KM, et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A. 2008;105(5):1733–1738.
   PubMed Web of Science ®Google Scholar
• Hubbard PA, Shen AL, Paschke R, et al. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem. 2001;276(31):29163–29170.
   PubMed Web of Science ®Google Scholar
• Oneda B, Crettol S, Jaquenoud Sirot E, et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics. 2009;19(11):877–883.
   PubMed Web of Science ®Google Scholar
• Zhang JJ, Zhang H, Ding XL, et al. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol. 2013;69(4):807–812.
   PubMed Web of Science ®Google Scholar
• Elens L, Hesselink DA, Bouamar R, et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014;36(1):71–79.
   PubMed Web of Science ®Google Scholar
• Lunde I, Bremer S, Midtvedt K, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014;70(6):685–693.
   PubMed Web of Science ®Google Scholar
• Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62(3):248–260.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525–528.
   PubMed Web of Science ®Google Scholar
• Shuker N, Bouamar R, Weimar W, et al. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta. 2012;413(17–18):1326–1337.
   PubMed Web of Science ®Google Scholar
• Vafadari R, Bouamar R, Hesselink DA, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 2013;35(4):459–465.
   PubMed Web of Science ®Google Scholar
• Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11(5):703–714.
   PubMed Web of Science ®Google Scholar
• Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012;91(6):1044–1052.
   PubMed Web of Science ®Google Scholar
• Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48(12):805–816.
   PubMed Web of Science ®Google Scholar
• Barraclough KA, Isbel NM, Lee KJ, et al. NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation. 2012;94(10):1025–1032.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant. 1998;13(9):2322–2326.
   PubMed Web of Science ®Google Scholar
• Noll BD, Coller JK, Somogyi AA, et al. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies–a method suitable for small (<1 mg) samples. Ther Drug Monit. 2011;33(6):688–693.
   PubMed Web of Science ®Google Scholar
• Noll BD, Coller JK, Somogyi AA, et al. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther Drug Monit. 2013;35(5):617–623.
   PubMed Web of Science ®Google Scholar
• Murray GI, McFadyen MC, Mitchell RT, et al. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer. 1999;79(11–12):1836–1842.
   PubMed Web of Science ®Google Scholar
• Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 2002;30(10):1108–1114.
   PubMed Web of Science ®Google Scholar
• Zheng S, Tasnif Y, Hebert MF, et al. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther. 2012;92(6):737–745.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Naesens M, de Jonge H, et al. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 2010;32(4):394–404.
   PubMed Web of Science ®Google Scholar
• Chen JS, Li LS, Cheng DR, et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc. 2009;41(5):1557–1561.
   PubMed Web of Science ®Google Scholar
• Quteineh L, Verstuyft C, Furlan V, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008;103(6):546–552.
   PubMed Web of Science ®Google Scholar
• Naesens M, Lerut E, De Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20(11):2468–2480.
   PubMed Web of Science ®Google Scholar
• Ma J, Divers J, Palmer ND, et al. Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation. Kidney Int. 2015;88(3):584–592.
   PubMed Web of Science ®Google Scholar
• Tavira B, Gomez J, Diaz-Corte C, et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. J Hum Genet. 2015;60(5):273–276.
   PubMed Web of Science ®Google Scholar
• Moore J, McKnight AJ, Dohler B, et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol. 2012;23(11):1891–1899.
   PubMed Web of Science ®Google Scholar
• Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant. 2011;11(12):2635–2646.
   PubMed Web of Science ®Google Scholar
• Bloch J, Hazzan M, van der Hauwaert C, et al. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. Pharmacogenomics. 2014;15(16):2011–2024.
   PubMed Web of Science ®Google Scholar
• Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol. 2000;279(6):F96–F81.
   Web of Science ®Google Scholar
• Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285(5431):1276–1279.
   PubMed Web of Science ®Google Scholar
• Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82(1):131–185.
   PubMed Web of Science ®Google Scholar
• Smith HE, Jones JP 3rd, Kalhorn TF, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics. 2008;18(11):943–953.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Garcia-Cerrada M, Coto E, et al. A 3ʹ-UTR polymorphism in soluble epoxide hydrolase gene is associated with acute rejection in renal transplant recipients. PLoS One. 2015;10(7):e0133563.
   PubMed Web of Science ®Google Scholar
• Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet. 2004;364(9447):1814–1827.
   PubMed Web of Science ®Google Scholar
• Yarlagadda SG, Coca SG, Garg AX, et al. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant. 2008;23(9):2995–3003.
   PubMed Web of Science ®Google Scholar
• Ghods AJ, Savaj S, Abbasi M, et al. The incidence and risk factors of delayed graft function in 689 consecutive living unrelated donor renal transplantation. Transplant Proc. 2007;39(4):846–847.
   PubMed Web of Science ®Google Scholar
• Hauser IA, Kruck S, Gauer S, et al. Human pregnane X receptor genotype of the donor but not of the recipient is a risk factor for delayed graft function after renal transplantation. Clin Pharmacol Ther. 2012;91(5):905–916.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, et al. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther. 2010;32(12):2012–2023.
   PubMed Web of Science ®Google Scholar
• Elens L, Bouamar R, Hesselink DA, et al. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22(5):373–380.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Garcia M, Macias RM, et al. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol. 2013;53(4):427–434.
   PubMed Web of Science ®Google Scholar
• Israni A, Leduc R, Holmes J, et al. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation. 2010;90(12):1401–1408.
   PubMed Web of Science ®Google Scholar
• Oetting WS, Schladt DP, Leduc RE, et al. Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. Transpl Int. 2011;24(12):1231–1238.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Hesselink DA. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?. Clin Pharmacol Ther. 2010;87(6):640–641.
   PubMed Web of Science ®Google Scholar
• Yates CJ, Fourlanos S, Hjelmesaeth J, et al. New-onset diabetes after kidney transplantation-changes and challenges. Am J Transplant. 2012;12(4):820–828.
   PubMed Web of Science ®Google Scholar
• Elens L, Sombogaard F, Hesselink DA, et al. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-alpha are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genomics. 2013;23(12):649–657.
   PubMed Web of Science ®Google Scholar
• Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation. 2005;80(10):1419–1424.
   PubMed Web of Science ®Google Scholar
• Bamoulid J, Courivaud C, Deschamps M, et al. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol. 2006;17(8):2333–2340.
   PubMed Web of Science ®Google Scholar
• Kang ES, Kim MS, Kim YS, et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care. 2008;31(1):63–68.
   PubMed Web of Science ®Google Scholar
• Kang ES, Kim MS, Kim YS, et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes. 2008;57(4):1043–1047.
   PubMed Web of Science ®Google Scholar
• Ghisdal L, Baron C, Le Meur Y, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol. 2009;20(11):2459–2467.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535–546.
   PubMed Web of Science ®Google Scholar
• Ferraresso M, Turolo S, Ghio L, et al. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors. Clin Exp Hypertens. 2011;33(6):359–365.
   PubMed Web of Science ®Google Scholar
• Torio A, Auyanet I, Montes-Ares O, et al. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients. Transplant Proc. 2012;44(9):2596–2598.
   PubMed Web of Science ®Google Scholar
• Moes AD, Hesselink DA, Zietse R, et al. Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Pharmacogenomics. 2014;15(9):1243–1251.
   PubMed Web of Science ®Google Scholar
• Chen SY, Li JL, Meng FH, et al. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism–a prospective, randomized, controlled study. Clin Transplant. 2013;27(3):E272–E281.
   PubMed Web of Science ®Google Scholar
• Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7(11):937–942.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695–698.
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res. 1999;16(8):1213–1218.
   PubMed Web of Science ®Google Scholar
• Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002;74(4):571–572.
   PubMed Web of Science ®Google Scholar
• Yanagimachi M, Naruto T, Tanoshima R, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant. 2010;24(6):855–861.
   PubMed Web of Science ®Google Scholar
• Vadivel N, Garg A, Holt DW, et al. Tacrolimus dose in black renal transplant recipients. Transplantation. 2007;83(7):997–999.
   PubMed Web of Science ®Google Scholar
• Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011;91(3):300–308.
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5(3):243–272.
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao HP, Liu CX, et al. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev. 2007;39(4):699–721.
   PubMed Web of Science ®Google Scholar
• McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8(3):371–382.
   PubMed Web of Science ®Google Scholar
• Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11(4):274–286.
   PubMed Web of Science ®Google Scholar
• Scheiner MA, Damasceno AM, Maia RC. ABCB1 single nucleotide polymorphisms in the Brazilian population. Mol Biol Rep. 2010;37(1):111–118.
   PubMed Web of Science ®Google Scholar
• Gaynor JJ, Ciancio G, Guerra G, et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int. 2016;29(2):216–226.
   PubMed Web of Science ®Google Scholar
• Ng FL, Holt DW, Chang RW, et al. Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrol Dial Transplant. 2010;25(2):628–634.
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cyp3a5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19–24.
   PubMed Web of Science ®Google Scholar
• Sanghavi K, Brundage RC, Miller MB, et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J. 2015. DOI:10.1038/tpj.2015.87.
   PubMed Web of Science ®Google Scholar
• Oetting WS, Schladt DP, Guan W, et al. Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple cyp3a5 alleles. Am J Transplant. 2016;16(2):574–582.
   PubMed Web of Science ®Google Scholar
• Lai Y, Zhang J, Wang YX, et al. CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups. Pharmazie. 2011;66(2):136–140.
   PubMed Web of Science ®Google Scholar
• Li D, Zhang GL, Lou YQ, et al. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther. 2007;32(1):89–95.
   PubMed Web of Science ®Google Scholar
• van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch caucasians. Clin Chem. 2002;48(10):1668–1671.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Vizcaino S, Gasiba C, et al. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between spaniards and other caucasian populations. Ther Drug Monit. 2005;27(6):819–821.
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Hermann R, Huennemeyer A, et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther. 2006;79(4):339–349.
   PubMed Web of Science ®Google Scholar
• Apellaniz-Ruiz M, Inglada-Perez L, Naranjo ME, et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 2015;15(3):288–292.
   PubMed Web of Science ®Google Scholar
• Andrews LM, Riva N, de Winter BC, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol. 2015;11(6):921–936.
   PubMed Web of Science ®Google Scholar
• Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948–957.
   PubMed Web of Science ®Google Scholar
• Passey C, Birnbaum AK, Brundage RC, et al. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics. 2012;13(10):1141–1147.
   PubMed Web of Science ®Google Scholar
• Boughton O, Borgulya G, Cecconi M, et al. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br J Clin Pharmacol. 2013;76(3):425–431.
   PubMed Web of Science ®Google Scholar
• Elens L, Hesselink DA, van Schaik RH, et al. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol. 2013;75(6):1545–1547.
   PubMed Web of Science ®Google Scholar
• Storset E, Asberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients–a prospective, randomized study. Transplantation. 2015;99(10):2158–2166.
   PubMed Web of Science ®Google Scholar
• de Graav GN, Bergan S, Baan CC, et al. Therapeutic drug monitoring of belatacept in kidney transplantation. Ther Drug Monit. 2015;37(5):560–567.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(4):333–343.
   PubMed Web of Science ®Google Scholar